Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC
March 3rd 2023Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Read More